Key Takeaways
- “Immunotherapy” is an umbrella term, not a regimen. Immune checkpoint inhibitors, CAR T-cell therapy, treatment vaccines and other approaches are clinically different.
- Match the exact generic drug and combination to the cancer type, stage, line of treatment, biomarker requirements and current indication. A positive PD-L1 result is not a universal guarantee of benefit.
- Checkpoint inhibitors can inflame healthy organs. New diarrhoea, cough, breathlessness, jaundice, weakness, confusion or hormonal symptoms deserve prompt assessment—even after treatment has stopped.
- Tell the oncologist about autoimmune disease, organ or stem-cell transplantation, chronic infections and prior immune toxicity before treatment is booked.
- Carry an immunotherapy alert record across borders. Emergency clinicians need the drug name, last dose, treating contact and prior immune-related adverse events.
Content
Immunotherapy is often marketed as if it were one modern alternative to chemotherapy. It is not. The term includes treatments that release immune “brakes,” therapies that modify or transfer immune cells, antibodies, vaccines and immune-system modulators.[1] Their preparation, risks, hospital requirements and follow-up are not interchangeable. This guide concentrates on immune checkpoint inhibitors—such as drugs aimed at PD-1, PD-L1 or CTLA-4—because these are widely used systemic treatments for several cancers. CAR T-cell and other cell therapies require a separate assessment of manufacturing, admission, cytokine-release syndrome and neurologic risk.
Question 1: What exactly is being recommended?
Ask for the generic name, not only a brand or a phrase such as “domestic PD-1.” The written proposal should state whether it is a single checkpoint inhibitor or a combination with chemotherapy, targeted therapy, another checkpoint inhibitor or another modality. It should also record dose, interval, treatment intent, planned reassessment and a stopping rule.
Checkpoint proteins normally help prevent an immune response from damaging healthy cells. Blocking PD-1/PD-L1 or CTLA-4 can restore T-cell activity against some tumours, but it can also remove part of that protection.[2] That mechanism explains both the possibility of durable benefit and the unusual pattern of toxicity; it does not mean the immune system will recognise every cancer.
For treatment in China, request the current Chinese prescribing information and verify that the proposed product, manufacturer and indication are authorised. The National Health Commission's 2025 guidance is updated by tumour type and individual medicine and emphasises pathological confirmation, required target testing, adherence to indications and attention to drug-related adverse reactions.[3] If the proposed use falls outside the labelled indication, ask what evidence supports it, whether the hospital has approved the expanded use, what alternatives exist and who pays. China's antineoplastic-drug management measure sets an institutional pathway and informed-consent requirements for qualifying expanded use; a coordinator's verbal assurance is not that pathway.[4]
Question 2: What evidence makes this patient a candidate?
The answer should join four pieces: tumour type, disease setting, treatment history and biomarker context. PD-L1 expression, mismatch-repair deficiency or microsatellite instability, tumour mutational burden and other molecular features may matter in particular indications. None is a universal “immunotherapy score,” and test requirements differ by drug and cancer.
Ask for the complete biomarker report, not a cropped result. It should identify the specimen, test date, assay, laboratory, scoring method and result. For PD-L1, the relevant score may be tumour proportion score, combined positive score or another defined method; a percentage without its method can be misleading. Also confirm whether the tissue predates important intervening treatment and whether the pathologist considers it adequate.
The National Health Commission's cancer-quality plan states that antineoplastic use should have pathological support and that drugs with a defined target should have target-testing support.[5] Biomarkers can enrich the chance of response, but they do not promise it. Conversely, some approved indications do not require a positive PD-L1 result. The oncologist should point to the evidence for the exact clinical situation, not borrow response rates from a different tumour or treatment line.
Question 3: What in the medical history changes risk?
Before travel, provide a dated record of all cancer therapy and a full problem list. Specifically flag:
- autoimmune disease, including inflammatory bowel, rheumatologic, neurologic, endocrine and skin conditions;
- solid-organ or allogeneic stem-cell transplantation;
- previous pneumonitis, hepatitis, myocarditis, colitis or serious drug rash;
- hepatitis, HIV, tuberculosis or another chronic or recent infection;
- current or recent steroids, immunosuppressants and anticoagulants;
- baseline bowel frequency, cough, exercise tolerance, skin condition, neurologic symptoms and hormone replacement;
- pregnancy possibility and fertility priorities.
Pre-existing autoimmune disease is not a detail to discover after infusion. NCI specifically advises discussing it before checkpoint treatment.[6] Transplant recipients may face graft rejection or graft-versus-host complications, and these decisions usually need input from both oncology and the transplant team. The right question is not “Is this an absolute ban?” but “What is the estimated benefit, what extra risk applies here, and can the hospital manage that complication?”
Question 4: What is the baseline and cycle-monitoring plan?
Baseline assessment makes a later change interpretable. Depending on the drug, combination and history, the team may review blood count, liver and kidney function, thyroid tests, glucose, electrolytes and other endocrine or cardiac markers, as well as relevant imaging and oxygenation. There is no single universal panel; ask which results are required before every dose and which are repeated only when symptoms arise.
Keep copies in the original units and reference ranges. A rising liver enzyme or falling thyroid hormone may be clinically important even when the patient feels well. Each visit should include active symptom questions, not just an infusion appointment.
Response assessment also needs context. Tumours can grow because treatment is ineffective, because of inflammation, or for another reason; “pseudoprogression” should never be used casually to explain deterioration. If imaging worsens, ask whether the patient is clinically stable, whether confirmatory imaging is appropriate, and what criteria the team uses to continue or change treatment. Continuing automatically can delay effective alternatives.
Question 5: Who handles immune-related adverse events?
Checkpoint inhibitors can cause the immune system to inflame normal organs. NCI notes that effects vary, can occur at any point during or after treatment and may be serious or life-threatening.[6][7] Possible presentations include:
- diarrhoea, abdominal pain, black or bloody stool;
- new cough, breathlessness or chest pain;
- yellow skin or eyes, dark urine, severe nausea or unusual bruising;
- widespread rash, blistering or painful mouth sores;
- marked thirst, frequent urination, dizziness, headache, unusual cold intolerance or profound fatigue;
- new weakness, numbness, drooping eyelids, confusion, seizures or trouble walking.
This is not a self-diagnosis list—many infections, tumour complications and other medicines can cause the same symptoms. It is a reason to obtain timely assessment and to tell the clinician about checkpoint therapy. The ASCO guideline organises diagnosis and management by affected system and toxicity severity; treatment may be held and corticosteroids or other immunosuppression used, but the approach varies substantially by organ.[8] Patients should not start leftover steroids or stop essential hormone replacement without clinical advice.
Before the first dose, obtain:
- a 24-hour oncology number and the hospital's emergency destination;
- symptom-specific same-day and emergency instructions;
- the name of the clinician who manages toxicity after the patient leaves China;
- a plan for urgent laboratory tests and imaging in the home country;
- an immunotherapy alert card or phone record in both languages.
The alert should show the generic drug, combination, dates and last dose; the treating hospital and oncologist; known allergies; previous immune toxicity; current steroid or hormone-replacement treatment; and the instruction to consider an immune-related adverse event. It should not contain only a QR code that a foreign emergency department cannot open.
Question 6: How long is the commitment—and what is included in the cost?
Clarify whether duration is defined by a fixed number of cycles, a maximum time, response, unacceptable toxicity or disease progression. Ask what happens if treatment is held: are monitoring and specialist consultations included, can unused medicine be refunded, and who pays for admission or immunosuppressive treatment? Combination regimens should separate each drug, administration charge, laboratory test and response scan.
An infusion can finish in an hour while follow-up lasts months. Some endocrine injury may require long-term hormone replacement, and new immune-related problems may begin after the final dose.[7] The handover plan therefore needs more than a “next scan” date. It should specify monitoring results, unresolved symptoms, prior toxicity grade and treatment, steroid taper if any, next planned dose, criteria for restarting and the clinical owner at home.
Medical disclaimer: This guide provides general education and does not determine eligibility for immunotherapy or manage an adverse event. New or rapidly worsening symptoms during or after immunotherapy require prompt evaluation by clinicians who know the exact treatment. Severe breathing difficulty, chest pain, confusion, weakness or other emergency symptoms need immediate local care.
Related Hospitals
List only institutions whose tumour-specific oncology team, pharmacy, immune-toxicity pathway and international follow-up arrangements have been verified.
Related Treatments
Separate checkpoint inhibitors from cell therapy and clinical trials. Link a medicine only after verifying the current product, indication and hospital availability.
Related Guides
- Biomarker testing before cancer treatment
- Chemotherapy planning and safety
- Multidisciplinary cancer care
- Emergency planning after treatment abroad
FAQ
Is PD-L1 positivity proof that immunotherapy will work?
No. PD-L1 can help select treatment in certain cancer-specific indications, but the assay, scoring method and cut-off matter, and responses are not guaranteed. Some approved settings do not require PD-L1 positivity.
Is immunotherapy always gentler than chemotherapy?
No. It often has a different side-effect pattern, not an absence of risk. Checkpoint inhibitors can cause immune inflammation in almost any organ, including rare severe events.[6][7]
Can immune-related side effects begin after the last infusion?
Yes. NCI notes that adverse effects can occur during and after treatment. Keep the alert record and make sure the home-country team knows the drug and last-dose date.[7]
Should I take steroids on my own if I suspect an immune reaction?
No. Steroids are important for some immune-related adverse events, but the dose, urgency and taper depend on the organ and severity; infection and other causes must also be considered. Seek clinical advice promptly.[8]
Is CAR T-cell therapy just another immune checkpoint infusion?
No. CAR T-cell therapy involves collecting and modifying immune cells and has different eligibility, manufacturing, admission and acute-toxicity requirements. It needs a separate centre and treatment assessment.[1]
Sources
- US National Cancer Institute — Immunotherapy to Treat Cancer
- US National Cancer Institute — Immune Checkpoint Inhibitors
- National Health Commission of China — Guidelines for Clinical Application of Novel Antineoplastic Drugs (2025 Edition)
- National Health Commission of China — Measures for Clinical Application Management of Antineoplastic Drugs (Trial)
- National Health Commission of China — Action Plan to Improve the Quality of Cancer Diagnosis and Treatment
- US National Cancer Institute — Organ-Related Inflammation and Immunotherapy
- US National Cancer Institute — Side Effects of Immunotherapy
- ASCO Guideline Update — Management of Immune-Related Adverse Events
Hero Image Review
- Decision: Rejected; replacement pending as hero-reviewed.png.
- Why: The original repeats the generic doctor–patient consultation composition and uses abstract shield, cell and IV icons that do not show an immunotherapy-specific clinical decision or safety task.
- Replacement brief: Natural 16:9 oncology consultation: patient and oncologist review a simple, non-readable body-system monitoring checklist and an immunotherapy alert card, with a companion present; documentary lighting, no molecular graphics, shield metaphors, logos, drug brands, personal data, visible needles or futuristic effects.